<DOC>
	<DOCNO>NCT01763554</DOCNO>
	<brief_summary>Review medical file 69 patient neuroendocrine tumour treat CCI January/10 - July/12 Lutetium-177 DOTA-TATE Health Canada 's Special Access Programme ( SAP ) . Efficacy , safety , relevant data collect .</brief_summary>
	<brief_title>Review Medical Records Patients Who Have Been Treated With Lutetium Cross Cancer Institute Between January 2010 July 31 , 2012</brief_title>
	<detailed_description>Neuroendocrine tumour comprise spectrum rare neoplasm . Data analysis conduct obtain efficacy , safety , relevant data Lu-177 DOTA-TATE treatment .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>Male female ≥ 14 90 year age Presence histologically proven NET tumour ( ) Serum creatinine ≤ 150 µmol/L , measure GFR use plasma clearance ≥50 mL/min Haemoglobin concentration 5.5 mmol/L ; WBC ≥ 2*109/L ; platelet ≥ 100*109/L Liver function test ( serum albumin , total bilirubin , ALT , AST alkaline phosphatase ) ≤ 3X upper limit normal Potential surgery curative intent Surgery , radiation therapy , cytotoxic chemotherapy , embolization investigative therapy ( interferon , mTOR inhibitor ) within 12 week enrollment Known brain metastasis unless metastasis treat stabilized ( confirmed CT ) ≥ 6 month prior enrollment Uncontrolled congestive heart failure Receiving concomitant medication decrease renal function Uncontrolled diabetes mellitus Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lu-177</keyword>
	<keyword>Lutetium-177</keyword>
	<keyword>DOTA-TATE</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>radiopharmaceutical</keyword>
</DOC>